Unit 1 - Molecular Targeted Therapy Flashcards Preview

MSII Pharmacology > Unit 1 - Molecular Targeted Therapy > Flashcards

Flashcards in Unit 1 - Molecular Targeted Therapy Deck (32):
1

explain what preclinical studies are

new drug is tested on normal and cancer cell lines in a laboratory setting
-lab investigation involves animal testing for efficacy and toxicity

2

explain what an investigational new drug (IND) application is

new drug sponsor files an IND application with FDA for clinical testing in humans
-if FDA approves application, clinical trials start

3

explain what phase I trials are

determine safe and appropriate dose for subsequent studies
-have 10-30 pts with different malignancies that failed standard treatment, and life expectancy of at least 1-2 months with functioning organs capable of drug metabolism and excretion
-highest dose with acceptable toxicity is recommended for PII

4

explain what phase II trials are

determine effectiveness and side effects of new drug
-have up to 100 pts with same type of malignancy for which no effective treatment is available and/or are most likely to respond to therapy, with life expectancy at least 3 mo and functioning organs with limited number of prior treatments
-patients are closely monitored and immediately removed from treatment if condition worsens

5

explain what phase III trials are

evaluates effectiveness of new drug, and compares it to best available standard treatment
-large and long-term trials with 100-1000s of patients whose eligibility depends on disease setage, first time treatment, status, goals, etc.

6

explain what a new drug application is

drug sponsor files NDA or BLA (biologics license application) with FDA
-sponsor submits phase III trial data indicating new drug is safe and superior to standard treatment

7

explain what FDA approval is

if satisfied with phase III results, FDA approves new drug, which can take ~1.5 years
-after approval, drug can be marketed to public under a label that indicates dosage, safety, indications, and side effects

8

explain what phase IV trails are

determine long-term safety and effectivfeness of new drug
-since III isn't long enough to see long-term problems

9

mechanism of action of Imatinib (Gleevec)

selective activity against Abl tyrosine kinase of CML
-binds to Bcr-Abl at same site where ATP binds, thus blocking Bcr-Abl's ability to phosphorylate and activate proteins involved in malignant transformation

10

toxicity of Imatinib (Geevec)

minimal side effects, including nausea, vomiting, fluid retention, muscle cramps, and arthralgia
-myelosuppression in 29% of patients

11

why was there intrinsic resistance to Imatinib (Gleevec)?

if persistent Bcr-Abl kinase activity, could be due to:
-mutations in Bcr-Abl kinase, making it insensitive to drug
-drug unable to reach target b/c enhanced binding to other proteins in circulation and/or drug efflux

12

why was there relapse after initial responses to Imatinib?

mostly involves reactivation of Bcr-Abl kinase
-if mutations in Abl kinase, mutant kinase becomes less sensitive to drug
-unknown mechanism behind patients with Bcr-Abl amplification
, or persistent inhibition of Bcr-Abl kinase

13

what are Nilotinib and Dasatinib?

2nd generation TKIs
-Nilotinib: better fit in ABL pocket (20-30x potency) and more effective if Imatinib-resistant
-Dasatinib: side effect is pulmonary arterial HTN (PAH)

14

explain what GISTs are

gastrointestinal stromal tumors; most common mesenchymal malignancy of GIT (~1%)
-benign and malignant, but all GISTs are potentially malignant
-commonly stomach > SI > esophagus > colon > rectum
-don't involve lymph nodes, but metastasize to liver
-generally in older adults
-90% are KIT (CD117)+, 5% have PDGFRA mutations (both are TK receptors)

15

how does imatinib treat GIST?

inhibits KIT and PDGFRA at 400 mg/day (although up to 800 mg/d is safe, no better effect)

16

explain what the Ph+ in CML is

Philadelphia Xm in >90% of cases, that's a reciprocal translocation between Xm 9 and 22
-t(9,22) fuses BCR gene on Xm 22 with ABL gene from Xm 9, creating famous Bcr-Abl fusion protein

17

explain what the PML-RARalpha in APL is

reciprocal translocation between Xm 15 and 17 in 98% of cases
-fuses retinoic acid receptor alpha gene with promyelocytic leukemia gene to make PML-RAR-alpha

18

explain the mechanism of action of retinoic acid in APL

induces terminal differentiation of malignant cells that subsequently undergo natural apoptosis
-in normal cells, RA binds to its receptors including RAR-alpha, to induce expression of genes involved in myeloid cell differentiation
-at pharmacological concentration, RAR-alpha is activated via unknown mechanisms to induce expression of genes involved in myeloid cell differentiation

19

what is the toxicity of retinoic acid for APL?

if used alone, 1/3 of patients get increased WBC (leukocyte activation/retinoic acid syndrome)
-fever, respiratory distress, weight gain, pleural/pericardial effusion, renal failure

-if concurrent uses of chemo with retinoic acid plus corticosteroids, blocks LAS, but still has dryness of skin/lips, nausea, headache, arthralgia, bone pain

20

explain what the EGFR family members are

epidermal growth factor receptors in cancer development and progression
-ErbB1 (EGFR, HER1) is activated by EGF, TGF-alpha
-ErbB2 (HER2/neu) has no known ligand, but is the master coordinator that shares the ErbB ligands
-ErbB3 (HER3) is activated by neuregulin
-ERbB4 (HER4) is activated by neuregulin

21

in which cancers in ErB1 and 2 overexpressed

1: gastric, breast, prostate, bladder, ovarian, colorectal, non-small cell lung, glioblastoma

2: breast, ovarian, gastric

22

what is trastuzumab's target? mechanism?

against Erb-B2 (HER-2/neu) growth factor receptor
-seems to prevent transduction of proliferation and survival signals
-induces cytostatic growth inhibitory effects against ErbB2 overexpressing cells, due to Ab-induced downregulation and degradation of receptor
-monotherapy is modest response, but better if combined

23

what is trastuzumab's toxicity?

hypersensitivity reaction (even if humanized version)
-ventricular dysfunction and CHF
-can enhance cardiac toxicity of doxorubicin, so give in combo with taxanes

24

whats the mechanism of cetuximab and against what? its toxicity?

anti-ErbB1 monoclonal Ab
-competes for ligands to inhibit ErbB1 TK activity and growth promoting/survival signals
-works better with cisplatin and other standard chemotherapy agents
-causes pulmonary embolism and allergies

25

what is rituximab and its mechanism?

treatment for non-Hodgkin's lymphoma
-binds to CD20 Ag, which is TMP present on all B-cells
--eliminates CD20+ follicular lymphoma cells by: direct activation of apoptosis, complement activation, cell-mediated cytotoxicity

26

what are the most common types of cutaneous melanoma?

1. superficial spreading melanoma (70%)
2. nodular melanoma (15%; common in males >50, but occur at any age)
3. acral lentiginous melanoma (5%; more common in darker skinned)
4. Lentigo maligna melanoma (10%; common in middle aged to old)

27

what is the mutation most commonly attributed to cutaneous melanomas?

BRAF, which codes a serine threonine kinase
-V-->E most common, then V-->K

28

what drug is used to treat cutaneous melanomas? how does it work?

Vemurafenib is a BRAF inhibitor
-blocks constitutively activated pathway and downstream activity, decreasing cell proliferation and survival

29

side effects and contraindications of vemurafenib

arthralgia, fatigue, photosensitivity, alopecia, nausea, and diarrhea
-cutaneous squamous cell carcinoma, keratoacanthoma, or both
-QT prolongation, thus increased risk of ventricular arrhythmias
-new cutaneous melanoma

shouldn't be used if wild type BRAF, electrolyte abnormalities, or long QT syndrome

30

what is Dabrafenib used for? side effects?

next generation agent for treatment of cutaneous melanomas
-higher risk to develop cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma
-Serious febrile drug reactions (fever associated with hypotension, rigors, chills, dehydration, kidney failure)
-uveitis, iritis
-hyperglycemia (needs modification in DM management)
-may inhibit fertility in males

31

what is Trametinib used for? toxicities?

for cutaneous, unresectable or metastatic melanomas
-has different mech than usual
-causes cardiomyopathy, retinal pigment epithelial detachment, retinal vein occlusion, interstitial lung disease, serious skin toxicity, and may inhibit fertility in females
-shouldn't be given to patients previously treated with BRAF inhibitors

32

what is immunotherapy for melanoma?

1. ipilimumab (Yervoy); inhibits CTLA-4 to stimulate immune system
2. IL-2